IPAH: AI 评分 54/100 — AI 分析 (4月 2026)

Interpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter pharmaceuticals, supplying major retailers, wholesalers, and managed care organizations. Founded in 1984 and based in Hauppauge, New York, the company operates in the competitive pharmaceutical sector.

Key Facts: AI Score: 54/100 Sector: Healthcare

公司概况

概要：

Interpharm Holdings, Inc., founded in 1984, develops, manufactures, and markets generic prescription and over-the-counter pharmaceuticals. The company supplies major retailers, wholesalers, managed care organizations, and national distributors. Operating within the healthcare sector, Interpharm faces competition in the generic pharmaceutical market, with a focus on cost-effective medicine distribution.

IPAH是做什么的？

Interpharm Holdings, Inc., established in 1984, is a pharmaceutical company focused on the development, manufacture, and marketing of generic prescription strength and over-the-counter (OTC) pharmaceuticals. Headquartered in Hauppauge, New York, the company has built a business model centered around providing affordable medicine options to a broad customer base. Interpharm supplies its products to major retailers, wholesalers, managed care organizations, and national distributors, ensuring wide availability of its pharmaceutical offerings. The company's product portfolio includes a range of generic drugs, designed to offer cost-effective alternatives to brand-name medications. By focusing on generics, Interpharm aims to address the growing demand for affordable healthcare solutions. The company's operations encompass the entire pharmaceutical value chain, from product development and manufacturing to marketing and distribution. This integrated approach allows Interpharm to maintain control over quality and cost, enhancing its competitiveness in the market. Interpharm's strategy is to continue expanding its product portfolio and distribution network, solidifying its position as a key player in the generic pharmaceutical industry. As of 2026, Interpharm faces the challenges and opportunities inherent in the evolving healthcare landscape, including regulatory changes, pricing pressures, and increasing competition.

IPAH的投资论点是什么？

Interpharm Holdings, Inc. operates in the generic pharmaceutical market, characterized by high competition and pricing pressures. With a market capitalization of $0.00B and a negative P/E ratio of -0.02, the company's financial performance requires careful consideration. A gross margin of 28.7% indicates some ability to control production costs, but a negative profit margin of -18.6% raises concerns about overall profitability. Potential catalysts include expanding its product portfolio and distribution network. However, the company faces risks related to regulatory changes, competition, and pricing pressures. The negative beta of -120.16 suggests an inverse correlation with the market, which could provide some downside protection during market downturns. Investors should closely monitor the company's ability to improve profitability and manage its operational costs. The lack of dividend yield may deter income-focused investors.

IPAH在哪个行业运营？

Interpharm Holdings, Inc. operates within the medical-pharmaceuticals industry, a sector characterized by intense competition and regulatory scrutiny. The market is driven by an aging population, increasing prevalence of chronic diseases, and growing demand for affordable healthcare solutions. Generic drug manufacturers like Interpharm play a crucial role in providing cost-effective alternatives to brand-name medications. The industry faces challenges such as pricing pressures, patent expirations, and evolving regulatory landscapes. Competitors such as CBGL, DNAG, IMMB, INLB, and JNHMF operate in this space, each vying for market share. Growth opportunities exist through product innovation, strategic partnerships, and expansion into new markets.

Medical - Pharmaceuticals

Healthcare

IPAH有哪些增长机遇？

Expanding Product Portfolio: Interpharm can drive growth by expanding its portfolio of generic pharmaceuticals. Focusing on high-demand medications and therapeutic areas can attract a broader customer base. The global generics market is projected to reach $478.77 billion by 2030, presenting a substantial opportunity for Interpharm to increase its market share through strategic product development and launches. This expansion can be achieved within the next 2-3 years through internal R&D and strategic acquisitions.
Strategic Partnerships and Collaborations: Collaborating with other pharmaceutical companies, research institutions, and healthcare providers can provide access to new technologies, markets, and distribution channels. Strategic alliances can accelerate product development, reduce costs, and enhance market penetration. The pharmaceutical industry sees numerous collaborations annually, with deal values reaching billions of dollars. Interpharm can pursue partnerships within the next year to leverage external expertise and resources.
Geographic Expansion: Interpharm can explore opportunities to expand its operations into new geographic markets, particularly in emerging economies with growing healthcare needs. Entering new markets can diversify revenue streams and reduce reliance on domestic sales. The emerging markets pharmaceutical sector is expected to grow significantly, driven by increasing healthcare expenditure and access to medicines. Interpharm can target specific regions within the next 3-5 years, focusing on countries with favorable regulatory environments and market dynamics.
Focus on Over-the-Counter (OTC) Products: Expanding its range of over-the-counter (OTC) products can provide Interpharm with higher profit margins and a more stable revenue stream. OTC medications are less subject to pricing pressures and regulatory constraints compared to prescription drugs. The global OTC market is projected to reach $220 billion by 2027, offering significant growth potential. Interpharm can introduce new OTC products within the next 1-2 years, focusing on consumer health needs and market trends.
Enhancing Manufacturing Efficiency: Improving manufacturing processes and supply chain management can reduce costs, increase production capacity, and enhance product quality. Investing in advanced manufacturing technologies and automation can drive operational efficiency and improve competitiveness. The pharmaceutical industry is increasingly adopting lean manufacturing principles and digital technologies to optimize production processes. Interpharm can implement these improvements within the next year, resulting in cost savings and improved profitability.

Market capitalization of $0.00B indicates a small-cap company with potential for growth but also higher risk.
Negative P/E ratio of -0.02 reflects current losses, requiring investors to focus on future earnings potential.
Gross margin of 28.7% shows the company's ability to generate revenue from sales after deducting the cost of goods sold.
Negative profit margin of -18.6% highlights the company's struggle to achieve profitability, indicating high operating expenses or other financial challenges.
Beta of -120.16 suggests the stock price moves inversely to the market, potentially offering diversification benefits.

IPAH提供哪些产品和服务？

Develops generic prescription-strength pharmaceuticals.
Manufactures over-the-counter (OTC) medications.
Markets pharmaceutical products to various healthcare providers.
Supplies medicines to major retailers and wholesalers.
Distributes products to managed care organizations.
Provides pharmaceuticals to national distributors.
Focuses on cost-effective medicine options.

IPAH如何赚钱？

Develops and manufactures generic pharmaceuticals.
Markets and distributes products through various channels.
Generates revenue through the sale of prescription and OTC drugs.
Focuses on supplying affordable medicine options.

Major retailers (e.g., pharmacies, supermarkets).
Wholesalers (e.g., pharmaceutical distributors).
Managed care organizations (e.g., HMOs, PPOs).
National distributors (e.g., large-scale pharmaceutical suppliers).

Established distribution network with major retailers and wholesalers.
Expertise in generic pharmaceutical development and manufacturing.
Focus on cost-effective medicine options.
Long-standing presence in the pharmaceutical market (founded in 1984).

什么因素可能推动IPAH股价上涨？

Upcoming: Potential expansion of product portfolio with new generic drug launches in Q3 2026.
Upcoming: Strategic partnerships with major retailers to expand distribution network by Q4 2026.
Ongoing: Efforts to improve manufacturing efficiency and reduce operational costs throughout 2026.
Ongoing: Focus on increasing sales of over-the-counter (OTC) products to improve profit margins.

IPAH的主要风险是什么？

Potential: Intense competition in the generic pharmaceutical market could lead to pricing pressures.
Potential: Regulatory changes and compliance requirements could increase operational costs.
Potential: Patent expirations and intellectual property risks could impact product portfolio.
Ongoing: Negative profit margin (-18.6%) indicates financial instability.
Ongoing: Limited financial disclosure due to OTC Other tier status increases investment risk.

IPAH的核心优势是什么？

Established distribution network.
Expertise in generic pharmaceutical development.
Focus on cost-effective solutions.
Long-standing presence in the market.

IPAH的劣势是什么？

Negative profit margin (-18.6%).
Limited product diversification.
Small market capitalization ($0.00B).
Dependence on generic drug market.

IPAH有哪些机遇？

Expanding product portfolio.
Strategic partnerships and collaborations.
Geographic expansion into emerging markets.
Increasing focus on OTC products.

IPAH面临哪些威胁？

Intense competition in the generic pharmaceutical market.
Pricing pressures and regulatory changes.
Patent expirations and intellectual property risks.
Economic downturns affecting healthcare spending.

IPAH的竞争对手是谁？

Capital Bancorp, Inc. — Regional bank with some healthcare lending exposure. — (CBGL)
Dnage Group Ltd — Provider of genetic testing services. — (DNAG)
Immuron Ltd — Biopharmaceutical company focused on gut health. — (IMMB)
Inlab S.A. — Pharmaceutical company in Latin America. — (INLB)
Jianhe Biopharm Hldgs Ltd — Chinese biopharmaceutical company. — (JNHMF)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Raj Sutaria
Headquarters: Hauppauge, US
Employees: 670
Founded: 2000

AI Insight

AI analysis pending for IPAH

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Interpharm Holdings, Inc. do?

Interpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter (OTC) pharmaceuticals. The company supplies its medicines to major retailers, wholesalers, managed care organizations, and national distributors. By focusing on generic drugs, Interpharm aims to provide affordable healthcare solutions to a broad customer base. The company's business model encompasses the entire pharmaceutical value chain, from product development and manufacturing to marketing and distribution, ensuring quality control and cost-effectiveness.

What do analysts say about IPAH stock?

As of March 18, 2026, formal analyst ratings for Interpharm Holdings, Inc. (IPAH) are unavailable due to its listing on the OTC Other tier and limited coverage. Key valuation metrics such as P/E ratio (-0.02) and profit margin (-18.6%) suggest financial challenges. Investors should focus on the company's ability to improve profitability, expand its product portfolio, and navigate the competitive pharmaceutical market. The lack of analyst coverage necessitates independent research and due diligence.

What are the main risks for IPAH?

Interpharm Holdings, Inc. faces several risks, including intense competition in the generic pharmaceutical market, which can lead to pricing pressures and reduced profit margins. Regulatory changes and compliance requirements can increase operational costs and create uncertainty. Patent expirations and intellectual property risks could impact the company's product portfolio. The negative profit margin (-18.6%) indicates financial instability. Additionally, the limited financial disclosure due to its OTC Other tier status increases investment risk due to lack of transparency.